Fig. 6

Mifepristone treatment and the dynamics of TP53 mutations in normal breast tissue and suggested model for the prevention of triple negative breast cancer. a TP53 mutation frequency and b TP53 mutation count in normal breast tissue before and after mifepristone exposure in women who showed a decrease of the WID-Breast29 index after mifepristone (responders) and who did not show a decrease (non-responders); significance was assessed with the two-sided t-test. c Progesterone triggers release of RANKL in hormone receptor (HR) positive mature luminal cells leading to increased proliferation and thus accelerated mitotic ageing in HR negative luminal progenitor cells resulting in increased cancer risk; these effects are reduced after treatment with the progesterone antagonist mifepristone. HR, hormone receptor